Komboglyze

Metformin Hydrochloride and Saxagliptin, the active ingredient in Komboglyze, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control. GNH USA supplies Komboglyze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Komboglyze is an oral antidiabetic medication used to manage blood glucose in type 2 diabetes mellitus and related therapeutic pathways. - Type 2 diabetes mellitus: improves overall glycaemic control. - Adjunct to diet and exercise: helps achieve target HbA1c when lifestyle measures are insufficient. - Combination therapy: can be used with other antidiabetic agents for enhanced glucose lowering.

Komboglyze may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: loose stools often occurring early in therapy. - Abdominal pain: cramping or discomfort in the stomach area. - Headache: transient mild to moderate pain.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Komboglyze, several safety considerations should be reviewed. - Renal function: assess creatinine clearance to avoid accumulation. - Hepatic status: evaluate liver enzymes as impairment may increase risk. - Cardiac disease: monitor patients with heart failure closely. - Concomitant hypoglycaemic agents: adjust doses to prevent low blood sugar. - Elderly patients: start at lower doses and monitor tolerability. - Store at room temperature: keep in the original container, protect from moisture and heat.

Komboglyze can interact with various medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin or sulfonylureas: heightened risk of severe hypoglycaemia. - Severe renal impairment: increased metformin exposure leading to lactic acidosis. - Iodinated contrast agents: may precipitate renal dysfunction. - Strong CYP3A4 inhibitors: elevate saxagliptin plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal function when combined with metformin. - Diuretics: can alter fluid balance and renal clearance. - ACE inhibitors or ARBs: monitor renal parameters. - Beta‑blockers: may mask hypoglycaemic symptoms. - Alcohol: can potentiate metformin‑related lactic acidosis.